LVZP.F Stock Overview
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Livzon Pharmaceutical Group Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥3.11 |
52 Week High | CN¥3.11 |
52 Week Low | CN¥2.55 |
Beta | 0.43 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | -32.68% |
Change since IPO | -32.68% |
Recent News & Updates
Recent updates
Shareholder Returns
LVZP.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | 1.2% | 0.4% |
1Y | n/a | 25.8% | 28.8% |
Return vs Industry: Insufficient data to determine how LVZP.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LVZP.F performed against the US Market.
Price Volatility
LVZP.F volatility | |
---|---|
LVZP.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LVZP.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LVZP.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1985 | 9,005 | Yanggang Tang | https://www.livzon.com.cn |
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody.
Livzon Pharmaceutical Group Inc. Fundamentals Summary
LVZP.F fundamental statistics | |
---|---|
Market cap | US$4.41b |
Earnings (TTM) | US$271.03m |
Revenue (TTM) | US$1.76b |
18.5x
P/E Ratio2.9x
P/S RatioIs LVZP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LVZP.F income statement (TTM) | |
---|---|
Revenue | CN¥12.56b |
Cost of Revenue | CN¥4.66b |
Gross Profit | CN¥7.90b |
Other Expenses | CN¥5.97b |
Earnings | CN¥1.94b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 24, 2023
Earnings per share (EPS) | 2.08 |
Gross Margin | 62.91% |
Net Profit Margin | 15.43% |
Debt/Equity Ratio | 26.1% |
How did LVZP.F perform over the long term?
See historical performance and comparison